

Supplementary Table 1. Comparison between the two groups who were classified as subjects with high (≥ 3.8 kPa) and low MRE-LSM (< 3.8 kPa) based on the cutoff levels for the prediction of a significant hepatic fibrosis ($\geq F2$)

Characteristic	High MRE-LSM (≥ 3.8 kPa) (n=42)	Low MRE-LSM (< 3.8 kPa) (n=89)	P value
Age, yr	44.6 \pm 15.3	36.5 \pm 12.9	<0.05
Male sex	22 (52)	37 (41)	0.08
MRI-PDFF, %	16.7 \pm 10.4	12.6 \pm 9.8	<0.05
MRE-LSM, kPa	4.9 \pm 1.3	2.9 \pm 0.4	<0.001
R2*, s ⁻¹	55.4 \pm 14.5	53.9 \pm 16.2	0.18
CAP, dB/m	319.3 \pm 61.6	285.2 \pm 66.3	<0.05
TE-LSM, kPa	12.5 \pm 12.9	5.6 \pm 3.0	<0.001
Weight, kg	94.3 \pm 26.8	85.2 \pm 20.3	<0.05
BMI, kg/m ²	33.1 \pm 7.3	30.7 \pm 7.4	<0.05
WC, cm	106.8 \pm 16.9	98.5 \pm 16.9	<0.05
Hypertension	14 (33)	27 (30)	0.23
Type 2 diabetes mellitus	20 (47)	19 (21)	<0.05
AST, U/L	61.0 \pm 50.3	36.5 \pm 36.2	<0.001
ALT, U/L	84.2 \pm 84.6	49.4 \pm 59.6	<0.001
GGT, U/L	94.2 \pm 129.4	40.5 \pm 34.6	<0.001
ALP, U/L	98.8 \pm 91.7	65.4 \pm 20.4	<0.05
HDL-C, mg/dL	51.5 \pm 20.1	51.3 \pm 12.4	0.60
LDL-C, mg/dL	122.2 \pm 34.5	124.1 \pm 39.1	0.95
Triglycerides, mg/dL	159.7 \pm 89.3	138.6 \pm 96.8	0.22
WBC, $\times 10^9/L$	7.1 \pm 2.4	6.8 \pm 2.2	0.20
Platelet, $\times 10^9/L$	240.2 \pm 72.6	284.7 \pm 86.9	<0.05
HbA1c, %	6.7 \pm 1.7	6.1 \pm 1.6	0.12
Glucose, mg/dL	116.6 \pm 44.9	107.7 \pm 39.7	0.26
Insulin, $\mu U/mL$	20.7 \pm 14.9	21.0 \pm 29.5	0.58
HOMA-IR	6.1 \pm 5.0	6.2 \pm 10.6	0.64
Glucagon, pmol/L	12.9 \pm 9.0	12.8 \pm 7.7	0.80
C3, mg/dL	145.3 \pm 35.3	131.3 \pm 43.6	<0.05
C4, mg/dL	30.0 \pm 9.1	31.6 \pm 11.3	0.80
Cytokeratin-18, U/L	651.8 \pm 684.5	155.6 \pm 252.6	<0.001
Angiotensinogen, ng/mL	6.2 \pm 5.8	5.9 \pm 5.2	0.85
NFS	1.2 \pm 1.8	-0.2 \pm 1.2	<0.001
FIB-4	1.8 \pm 2.3	0.7 \pm 0.4	<0.05
APRI	0.9 \pm 0.8	0.4 \pm 0.3	<0.001
ELF score	9.4 \pm 0.9	8.5 \pm 0.8	<0.001
DXA total body fat, %	41.4 \pm 9.9	38.7 \pm 12.9	0.21
DXA total muscle, kg	40.5 \pm 23.8	45.8 \pm 14.2	0.51
MRI-visceral fat, cm ²	187.3 \pm 79.2	138.9 \pm 91.1	<0.05
MRI-subcutaneous fat, cm ²	296.8 \pm 143.1	243.5 \pm 125.5	<0.05

Values are presented as mean \pm standard deviation or number (%). All results are adjusted by age.

MRE, magnetic resonance elastography; LSM, liver stiffness measurement; MRI-PDFF, magnetic resonance imaging-estimated proton density fat fraction; R2*, R2* relaxation rate; CAP, controlled attenuation parameter; TE, transient elastography; BMI, body mass index; WC, waist circumference; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; WBC, white blood cell; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; C3, complement component 3; C4, complement component 4; NFS, nonalcoholic fatty liver disease fibrosis score; FIB-4, fibrosis-4; APRI, AST-to-platelet ratio index; ELF, enhanced liver fibrosis; DXA, dual-energy X-ray absorptiometry.